Increased CD200 levels in peripheral blood mononuclear cells of patients with primary Sjögren's syndrome. (17th March 2020)

• Record Type: Journal Article
• Authors: Liu, Ting‐Ting; Zeng, Xiang‐Peng; Gu, Ming‐Li; Deng, An‐Mei
• Is Part Of: International journal of rheumatic diseases. Volume 23:Number 5(2020)
• Page Start: 654
• Page End: 660
• Publication Date: 2020-03-17
• Subjects: CD200 -- IL‐17 -- peripheral blood mononuclear cell -- primary Sjögren's syndrome; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.13810
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Objectives: Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease with an unknown etiology. CD200 is associated with many autoimmune diseases, but little is known about its role in pSS. This study aims to correlate the expression of CD200 with pSS and evaluate its significance. Methods: Plasma CD200, CD200R, and interleukin (IL)‐17 levels were measured and analyzed by enzyme‐linked immunosorbent assay. Messenger RNA levels of CD200 and CD200R in peripheral blood mononuclear cells (PBMCs) were quantified by quantitative real‐time polymerase chain reaction (RT‐qPCR). Following pretreatment of CD200‐Fc, the protein levels of IL‐17A were measured in PBMCs from patients and healthy controls. Results: Results showed that, compared to CD200 in healthy controls, the relative levels in PBMCs from pSS were greater than 2‐fold. In addition, CD200 levels in plasma positively correlated with IL‐17 levels, as well as between plasma CD200 and pSS activity indexes (including immunoglobulin G and European League Against Rheumatism SS Disease Activity Index). While CD200R levels were significantly decreased in pSS patients, no correlation could be found. Furthermore, the protein level of IL‐17 decreased after pretreatment of CD200‐Fc in PBMCs from pSS patients. Conclusion: Our results suggested that the CD200/CD200R pathway is involved in pSS pathogenesis. It is hypothesized that regulation of IL‐17 expression affects Th17 differentiation. This newly discovered pathway could give rise to a novel targeted therapy for pSS.